Rivastigmine, also known as ENA-713, is a carbamate-derived reversible cholinesterase inhibitor that is selective for the central nervous system and is used for the treatment of Dementia, Alzheimer's Disease and Parkinson's Disease. It acts by covalently modifying a serine residue in the active site by carbamoylation, as it stabilizes or reduces the rate of decline in certain cognitive functions.
Properties:
Appearance & Physical State: White to Off-White Powder
Boiling Point: 316.2ºC at 760 mmHg
Melting Point: 123-125ºC
Flash Point: 145ºC
Vapor Pressure: 0.000416mmHg at 25°C
AChR Inhibitors Related Products:
Donepezil Hcl; (-)-Huperzine A; PNU-120596; Scopolamine hydrobromide; Darifenacin hydrobromide; Vinblastine sulfate; Tolterodine tartrate; Amfebutamone hydrochloride; Solifenacin; Solifenacin succinate; Trospium chloride; Pyridostigmine bromide; Varenicline; Revefenacin; Imidafenacin